Cost Analysis of Certolizumab Pegol Compared With Available Biologic Agents For Crohn’s Disease In Mexico And Brazil
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.521
https://www.valueinhealthjournal.com/article/S1098-3015(15)02597-8/fulltext
Title :
Cost Analysis of Certolizumab Pegol Compared With Available Biologic Agents For Crohn’s Disease In Mexico And Brazil
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02597-8&doi=10.1016/j.jval.2015.09.521
First page :
A866
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2738